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Given a dose of antigen, an organism may or may not respond by producing 
specific  antibody. The contending theories disagree on almost every detail of 
the mechanism set in motion; they are one in assuming that whatever is or fails 
to be produced, is specific.  Against the background of this tacit assumption any 
qualitative failure of the antibody response stands out as a major paradox. 
Thus it has been known for over 10 yr now that humans vaccinated against 
influenza produce antibodies against the immunlzhag antigen, but produce anti- 
bodies of higher titer against the antigen that was their first childhood experi- 
ence of influenza, even if that strain happened to be absent from the vaccine-- 
hence the name Original Antigenic Sin  (1).  The phenomenon rests on solid 
experimental foundations (2-11),  and has been reproduced in laboratory ani- 
mals (10,  12, 13). The evidence is incompatible with either of the reigning im- 
munological theories in their simplest form. On an instructive model the anti- 
body molecule would be moulded on the antigen and hence, by definition, must 
be more complementary to it than to any other antigen. On a selective model 
the antigen acts as mitogenic stimulus for cells predestined to form that partic- 
ular antibody; once again, the response should be most complementary to the 
antigen which triggered the proliferation of a particular clone of cells. 
Our studies were prompted by this paradox, and undertaken in the hope that 
a satisfactory solution might also teach us something about the production of 
antibodies in general. The work falls into three parts: (a) reexamination of the 
sera on which the Doctrine of Original Antigenic Sin was founded; (b) demon- 
stration of a basic difference between these and standard primary or secondary 
sera, together with a hypothesis to account for the observations; and (c) exper- 
imental tests of the new hypothesis. 
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Materials and Metkods 
Diluents.--Normal  saline (0.15  ~  NaC1 and 0.02 ~  phosphate buffer at pH 7.2)  was used 
in all tests, except when concentrating virus by adsorption-elution or when destroying non- 
specific inhibitors by the neuramiuidase of Vibrio cholerae. The diluent in these procedures was 
Ca-M  g-saline (14). 
Viruses.--A11 strains of influenza virus were drawn from the collection of the Virus Lab- 
oratory, School of Public Health, Ann Arbor. Fresh stocks were grown from the original freeze- 
dried preparations of the same viruses used in the vaccine trials (9,  11).  Dilute seed (about 
102 n)50) was inoculated into the ailantois of ll-day-old chick embryos. After 2 days' incuba- 
tion at 35°C the eggs were chilled, the allantoic fluids harvested aseptically, pooled, and ti- 
trated for hemagglutinin. For each 1000 hemagglutinating units of virus 1% v/v of washed 
and packed human erythrocytes were added, the suspension well mixed and incubated for 30 
rain at 4°C. The superuate was then pipetted off and the heavily agglutinated cells washed 
with two changes of approximately 20 times their volume of chilled normal saline. After the 
second  wash the packed cells were  taken up in  Ca-Mg-saline (~o  volume of  the original 
ailantoic fluid), and  incubated for 30 rain at 35°C  under genre stirring. At the end of this 
period the cells were spun out,  1% v/v of a  6% solution of NaN3 added to the supemate 
and the preparation stored at 4°C. Such elnates contained 90 to 95% of the virus originally 
present in the ailantoic fluid pool, and kept without change of titer for at least a  year. 
Sera.--Samples collected during field trials (9,  11) and stored without preservative at 4°C 
were inactivated by treatment with neuraminidase and subsequent heating at 62.5°C for 20 
min (15). The nonspecific inhibitory titers of human sera were reduced by this treatment to 
levels of  <5, without affecting their specific antiviral activity.  Such inactivated sera were 
stored frozen at -- 15°C. 
Test for Viral Hemagglu~inin.--Serial  2-fold dilutions of the trial samples were set out in 
plastic trays (WHO model), in 0.25 ml of normal saline, with the aid of Tak~tsy-loops. One 
standard drop (0.025  ml) of 5% fowl red cells was added from a calibrated dropping pipette, 
the trays shaken and the pattern of settled cells evaluated after 35 rain standing at room 
temperature. An agglutinaling dose is that amount of virus which causes partial (+) agglu- 
tination of the cells under these conditions; it corresponds to about 6 X  l0  s electron micro- 
scopicaliy visible particles. Nine intermediate degrees of agglutination were routinely read 
and the end point determined by interpolation where necessary. In this form the hemaggiu- 
tiuin test is reproducible to about  4-10%  (or ±0.05  log10 units). As a  rule,  all titrations 
were done in duplicate, 
Test for Antibody.--Antibody  directed against the V  antigen was assayed as antihemag- 
glutiuin. Samples of the inactivated sera were serially diluted in 0.25 ml normal saline and one 
standard drop  (0.025  ml) of saline containing exactly 4 agglutinating doses of the test virus 
was added to each cup. The trays were shaken, and incubated at room temperature for 60 
min. Then 0.025 ml of a  5% fowl red cell suspension was added to each cup, mixed, and the 
pattern of settled cells read after 35 rain at room temperature. This test is as reproducible 
as are hemagglutinin titrations, but the absolute titers vary with different fowl cells. For that 
reason only selected birds with similarly reacting ceils were used as donors, and all samples to 
be compared were always titrated  (in duplicate) on the same day, using erythrocytes of a 
single bird. 
Equilibrium Measurements.--The equipment (16) and the principles and practice of evalu- 
ation (17) have been fully described, and were used here without modification. An equilibrium 
test is basically a series of antibody titrations performed on the ultrafiltrates of an antiserum 
mixed with different doses of virus. As a rule each test was preceded by a range finding experi- 
ment. In this way the ten graded doses of antigen chosen for the main test were known to 
fall in the range of maximum information; i.e., where between 90 and 99.9% of antibody was s.  ~'AZEKAS DE  ST.GllOTH AND R.  G. WEBSTER  333 
complexed. Two controls, with saline replacing the antigen, were included in each test. The 
time allowed for equilibration was 30 rain (or about 3 times more than necessary), and the 
filters used for separating free antibody from the virus-antibody complex  were Millipore VM 
membranes of an average pore diameter of 50 4- 3 m#. Since large numbers of filtrations were 
performed each day, the data were processed on an IBM 7090 computer, the program per- 
forming the maximum likelihood fitting of the data to each of the four possible transforms of 
the mass law equation. Sets of data significantly deviating from linearity or not complying 
with the model on account of the intercepts or slope of the regression line are automatically 
rejected by this program. Such, however, were not found in this study. The final results are 
the weighted mean estimates of A, the number of antibody molecules/ml of serum, and of K, 
the  equilibrium constant  expressed in cgs-units. 
RESULTS 
Equilibrium Parameters of Ihe Test Sera.--The vaccine trials were run in the 
years 1954  (9) and 1955  (11), covering a wide range of age groups, using both 
monovalent and polyvalent vaccines. For the sake of simplicity, the youngest 
age group (4 to 8 yr) was chosen for study. These children had their first expo- 
sure to influenza after the emergence of the A  prime subtype (1946  to 1947), 
and could not have had experience of influenza A viruses other than those re- 
sembling the  type strain  FM1.  Two subgroups,  receiving either monovalent 
FM1 or SW vaccine were examined in detail.  The first of these should represent 
a  secondary response, the vaccine being homologous to the epidemic strains of 
the past 8 yr. The second~ receiving a  cross-reacting virus absent from human 
populations for at least 25 yr, should be regarded, formally at least, as respond- 
ing primarily. 
All prevaccination sera were first titrated against FM1 and SW virus. Forty- 
five of the 94 sera had measurable levels of antihemagglutinin against FM1 vi- 
rus and none against SW. Those having undetectable levels of anti-FM1 were not 
tested further as there was no way of deciding whether these children had es- 
caped natural infection with the prevalent epidemic strains and would thus re- 
spond primarily even to the FM1 vaccine, or whether they had been infected 
previously but either failed to respond or produced antibodies whose level was 
not maintained up to the time of the trials. All pairs of sera positive for anti- 
FM1 in the prevaccination bleed and available in quantities above 2.5 ml were 
tested by equilibrium filtration. The results obtained with sera from the  1954 
trial  (aqueous vaccines) are shown in Table I. 
Looking at the prevaccination status first, we find that the antibody against 
FM1 made up rather less than  1% of the average gamma globulin in human 
plasma (about 1@  6 molecules/ml). The averages of the two groups of children 
do not differ significantly and the ranges largely overlap. The equilibrium con- 
stants are of the order of 10  l~ for both groups, indicating antibody of very high 
quality since, at least in rabbits and fowls, one finds equilibrium constants of 
the order of 1013 in primary and of 10  it in secondary sera (18, 19). Corresponding 
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analogy. The same sera have no measurable antibody against SW virus, and 
hence the blank spaces ha Table I: reliable equilibrium measurements cannot be 
made on sera of antihemagglutinin fiters below 1:32. 
In the postvaccinafion bleeds after monovalent FM1 vaccine the average an- 
tihemagglutinin titers have risen by over tenfold, and this is reflected also in the 
number of antibody molecules. These rises are significant: even the lowest of the 
postvaccination sera score higher than any in the prevaccination set, by either 
measurement, and we are bound to conclude that substantial amounts of new 
TABLE  I 
Response 1o Aqueous  Vaccines 
Project:  Lapeer,  1954; groups A and C (9) 
Equilibrium parameters 
No. 
Vae-  Serum  of  clne  sam-  vs. FM1 antigen  vs. SW antigen 
ples 
K  A  aliA  K  A 
M1  Prevacci-  6  11.62 -4- 0.21 
nation  I  (11.40-11.93) 
Postvacci-  10  11.23 4- 0.18 
nation  (10.90-11.57) 
Prevacci-  6  11.584-0.24 
nntion  (11.17-11.85) 
Postvacci-  9  11.17  4-0.13 
nation  (10.97-11.41) 
13.48 -4-0.27 
(12.87-13.62) 
14.65 4- 0.26 
(14.33-15.03) 
13.85 4-0.27 
(13.01-14.11) 
14.92  4- 0.27 
(14.41-15.48) 
2.55 4- 0.211 
(2.02-2.70) 
4.02 4- 0.221 
(3.67-4.26) 
2.88  4- 0.3( 
(2.06-3.39) 
4.24 4- 0.29 
(3.64-4.8O) 
12.34 -4- 0.23 
(11.97-12.83) 
14.85  -I-0.31 
(14.35-15.59) 
aliA 
<1.5 
<1.6 
I (8  ×  <1.5 
[  1.63, 2.41 
<1.5 
3.51 q- 0.2~ 
(2.96-3.99) 
] 
The mean equilibrium  constants  (K), concentrations  of antibody  molecules/ml (A), and  anti- 
hemagglutinin  titers/ml (aliA) are given in log~0 units,  followed  by their standard  deviation and, 
in parentheses,  the range of observations. 
antibody had been formed. The quality of this new antibody is only slightly 
better than it was before vaccination and this, once again, suggests that these 
children had already secondary anti-FM1  in  their plasma when the  project 
began. 
The second group, given monovalent SW vaccine, reached almost  equally 
high antihemagglutinin levels, even though initially none of  the  subjects had 
any measurable anti-SW, and it is unlikely that any of them would have had 
previous acquaintance with this virus.Yet, about 7 % of their total gamma glob- 
ulin turned into anti-SW antibody (range 2 to 11%, with one exceptionally high 
value, 38 %). What is more, this antibody was of remarkably good quality, at 
least ten times better than what one should have expected. This combination of 
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nominally first experience. The left hand side of Table I  reveals three remark- 
able things: there was as much anti-FM1 produced after monovalent SW vac- 
nine as after homologous boosting; the quality of this antibody was just as good 
as after the homologous vaccine; and the number of antibody molecules was 
about the same when tested against one or the other antigen. 
The second set of sera, collected in 1955, represents responses to monovalent 
vaccines given in a water-in-oH adjuvant. The postvaccination bleedings were 
obtained 6 wk after vaccination, at the height of the antibody response (11). 
TABLE  II 
Response to  Water-in-oil Vaccines 
Project:  Coldwater,  1955; groups  I  and  III (11) 
Vac- 
cine  Serum 
FMI  Prevacci- 
nation 
Postvacci- 
nation 
SW  Prevacci- 
nation 
Postvacci- 
nation 
Equilibrium parameters 
No. 
I 
sam-  vs. FM1 antigen  vs. SW antigen 
pies 
K 
11.3'/  -4- 0.17 
(11.14-11.67) 
11.15 -4- 0.06 
(11.08-11.33) 
5  11.28  -4- 0.21 
(11.01-11.64) 
9  11.34 :/= 0.22 
(11.01-11.67) 
A  alia 
13.27 -4- 0.14  2.92  4- 0.11 
(12,98-13.51)  (2.80-3,21) 
14.72 -4- 0.27  3.76  :::k 0.2~ 
(14.16-15.00)  (3.34-4,22) 
13.71  -4- 0.22  3.19  4- 0.14 
(13.24-14.04)  (2.87-3,40) 
14.60 -4- 0.23  3.88  .4- 0.2~ 
(14.26-15.05)  (3.26-4.43) 
K 
11.87  -e-. 0.23 
(11.46-12.17) 
14.65  -4- 0.18 
(14.36-15.17) 
al~A 
<1.5 
<1.5 
<1.5 
3.20  -4- O.E 
(2.9O-3.48) 
The mean equilibrium  constants  (K), concentrations  of antibody  molecules/ml (A), and  anti- 
hemagglutinin  titers/ml (aliA) are  given in log10 units, followed by their  standard  deviation and, 
in parentheses,  the range of observations. 
This second set of children was essentially of the same age group as those re- 
ceiving aqueous vaccines and, judging by their prevaccination status,  of the 
same immunologic experience (Table II). At the inception of the trials their sera 
contained antibody of low titer but high quality against FM1, and none against 
SW. Their postvaccination responses are also much the same: a  great deal of 
new antibody was produced, the increase in quality on homologous boosting 
even less striking than in the previous group. Once again the consequences of 
Original Antigenic Sin are evident: there is a marked rise of anti-FM 1 after the 
SW vaccine, this antibody is of excellent quality and, as in the previous group, 
about the same number of molecules scoring as anti-FM1  and anti-SW. The 
conclusion that all sera contained secondary type antibody still holds, but its 
cogency is less in this group since the serum samples were taken 6 wk after im- 
munization, and it is conceivable that there might have been a  low primary 336  ORIGINAL  ANTIGENIC  SIN.  I 
response which was then boosted by the antigen persisting in the water-in-oil 
depot. 
Yet, the two sets of results (Tables I and II) are so similar that any interpre- 
tation based on disparate mechanisms would seem farfetched. The joint evi- 
dence indeed permits some quantitative conclusions. Thus, the effect of boosting 
with a cross-reacting antigen is manifested in Ca) the appearance of secondary 
TABLE III 
Distribution of Antibody in Absorbed and Dissociated Samples of Postvacdnation Sera 
Sera C/6 and A/7; Lapeer, 1954 (9) 
Vaccine 
FM1 
SW 
Absorbing  antigen 
FM1 
SW 
(Control) 
FM1 
SW 
(Control) 
Sample 
Supernate 
Dissociate 
Supernate 
Dissociate 
Supernate 
Dissociate 
Supernate 
Dissociate 
Supernate 
Dissociate 
Antlhemagglutlnln titer/ml* 
vs. FMI  vs.  SW 
3.96  2.05 
3.72  1.72 
3.99  <1.00 
2.78  1.90 
4.23  2.41 
4.61  3.92 
4.38  3.57 
4.12  3.41 
4.51  3.67 
4.60  3.62 
4.06  3.32 
4.82  4.02 
Difference 
of fiters* 
1.91 
2.00 
>2.99 
0.88 
1.82 
0.69 
0.81 
0.71 
0.84 
0.98 
0.74 
0.80 
* Logl0 units. 
looking antibody against the vaccinating virus; (b) the simultaneous appearance 
of high quality antibody against the originally experienced virus; and (c) that 
these are carried by the same number of molecules. The simplest logical step 
from here is to suppose that they register in identical numbers because they are 
on one and the same molecule. The next set of experiments was designed to test 
this proposition. 
Fractionation  of Secondary Sera.--An  antigen, when added to a  mixture of 
antibodies, will combine with the homologous component, the fraction of mole- 
cules bound being different in kind from the fraction left free. By the same pro- 
cedure subpopulations of cross-reacting antibodies can be removed from sera, 
this being the time-honoured method of preparing specific serological reagents. S. FAZEKAS DE ST.GI%OTH AND  R. G. WEBSTER  337 
In our experiments postvaccination sera were absorbed with different doses 
of virus, using both the vaccinating strain and the strain corresponding to the 
primary, natural exposure. The mixtures of virus and serum were held at room 
temperature for ~  hr and then spun at 35,000 g for 45 roin. As shown by control 
tests,  this treatment is sufficient to deposit over 99.9%  of the virus and, a 
fortiori, virus-antibody complexes; it does not measurably reduce the antibody 
titer of a serum. Thus the supernale removed from the absorption tubes repre- 
sents all of the unbound antibody. The deposit was then taken up in 0.1 
glycine buffer at pH 3.0 and dispersed by sonic treatment (Raytheon oscillator, 
60 sec at maximal output, at O°C). At this hydrogen ion concentration most of 
the formed antigen-antibody complexes dissociate, and thus after a second spin- 
ning at 35,000 g the supernate will contain the balance of antibodies present in 
the original serum. These dissociates were decanted from the virus pellets, ad- 
justed to neutrality with 0.6 ~  Aronsson-GrSnwall buffer (20), and made up to 
the original volume of serum. By determining equilibrium parameters on both 
samples against both viruses, we have a set of quantitative absorption data from 
which a complete balance sheet of antibodies can be drawn up. Table III shows 
the results obtained with a pair of sera from the group that had received aque- 
ous vaccines. 
Taking the response to the FM1 vaccine first, it is evident that an absorbing 
dose of FM1 virus which reduces the homologous titer to roughly half of its 
original value (54%), leaves about the same fraction of anti-SW behind (44%). 
The corresponding dissociate is also only slightly richer in antibody homologous 
to the absorbing virus, and this is shown by the closeness of ratios between ho- 
mologous and heterologous titers; 66:1 in the original serum, 81:1 in the super- 
hate, and 100:1 in the dissociate. When SW virus is used as absorbing agent, 
the shift is more striking. While the anti-SW component has completely disap- 
peared from the superaate (> 2S-fold reduction), the anti-FM1 titer is not even 
halved. In the dissociate, on the other hand, the ratio of anti-FM1 to anti-SW 
titers is 7.5:1, as against 66:1 in the original serum, or > 1000:1  in the super- 
hate. This serum thus behaves as a mixture containing a majority of molecules 
reacting with the vaccinating virus only (i.e. nonabsorbable by SW), together 
with some cross-reacting molecules (absorbable by SW, but capable of neutral- 
izing FM1). By and large this holds for all sera we have tested; in some instances 
there was also an indication that the cross-reacting antibodies belonged to the 
most avid sector of the antibody population: on more extensive homologous 
absorption the superuate was left relatively poorer in heterologous than homol- 
ogous antibody. 
The serum obtained in response to the SW vaccine behaved quite differently. 
The striking feature of these results is the constancy of the anti-FMl:anti-SW 
ratios. Whether we tested a large or a  small fraction of the original antibody, 
and whether these fractions had been bound or left behind by one or the other 338  ORIGINAL  ANTIGENIC  SIN. I 
of the absorbing viruses, within statistical variation the relative titers remained 
the same. Their ratio was 6.3 in the original serum, and the range of scatter was 
bounded by the values of 4.9 and 9.5. When this finding is evaluated against 
absorption results on standard sera (an example of which is shown in the top 
half of Table HI), there is no choice but to conclude that we are dealing with 
TABLE IV 
Equilibrium Parameters of Absorbed and Dissociated Samples of a Posbvaccination Serum 
Serum A/7; Lapecr, 1954 (9) 
Vaccine 
SW 
Absorbing 
antigen 
FM1 
SW 
(Control) 
Test  Sample*  antigen 
K  A 
Difference 
Supernate  FM1  11.68  -  0.48 
SW  12.16 
Dissociate  FM1  11.37  -- 0.53 
SW  11.90 
Supemate  FM1  11.55  --0.54 
SW  12.09 
Dissociate  FMI  11.28  --0.81 
SW  12.09 
Supernate  FM1  11.59  --  0.66 
SW  12.25 
Dissociate  FM1  11.39  --0.46 
SW  11.85 
Difference 
15.49  +0.03 
15.45 
14.88  --0.03 
14.91 
15.29  +0.32 
14.97[ 
14.99 I --0.03 
15.02  [ 
15.48  --0.05 
15.53 
14.53  -0.33 
14.86 
FM1  11.31  --0.66  15.53  --0.01 
SW  11.97  15.54 
The equilibrium constants  (K), concentrations  of antibody molecules/nil  (A), 
differences are given in log10 units. 
* The samples correspond to the entries in the lower half of Table HI. 
and their 
antibody molecules each of which is highly avid against two different antigens. 
This interpretation is the same as reached in the fundamental study of Jensen 
et al.  (10), where the double specificity of antibodies characteristic of the Orig- 
inal Antigenic Sin was clearly recognized. 
Yet,  since  this  conclusion is  unorthodox  and  would  set apart responses  to 
cross-stimulation  from both primary and secondary sera,  we also determined 
the equilibrium constants and the number of antibody molecules in each of the 
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Of the two parameters estimated by equilibrium measurements, the number 
of antibody molecules can be determined with greater accuracy. This value, un- 
like antihemagglutinin titers, is independent of the quality of antibodies and 
thus a sounder criterion for comparing concentrations of antibody, even apart 
from its greater inherent precision. It is evident from Table IV that the pairs of 
values obtained for each of the fractions are identical: within the accuracy of the 
method the differences between the numbers of anfi-FM1 and anti-SW mole- 
cules are not significant. This corroborates the conclusions drawn from anti- 
hemagglufinin tests (Table III). 
The behavior of the equilibrium constants, on the other hand, reveals a new 
aspect of the effect of boosting with related antigens. It appears that antibody 
molecules made in response to heterologous stimulation are not only uniformly 
cross-reactive, but also form a  homogeneous population.  Instead  of finding, 
as one would in a standard primary or secondary response, that the supernates 
after absorption contain antibody of poorer quality while the more avid frac- 
tions have been bound by the antigen and thus appeared in the dissociates, 
there is only the barest hint of such a  trend in this serum. Thus the mean of 
the K  values from the supernates is only 0.25 log units higher than the corre- 
sponding value for the original serum (0.10 >  P  >  0.05), while the dissociates 
are on the average 0.01 log units lower, which is statistically insignificant. A 
further point in favor of the homogeneity of this antibody population is the 
constancy of the  ratio of the  two equilibrium  constants  within  each of the 
fractions. There is no indication of preferential binding of one or the other kind 
of antibody, a  state of affairs difficult to visualize unless the two specificifies 
are carried by the same molecule. 
Homogeneity of the Antibody Population.--In view of the broad distribution 
of binding strengths in all antisera hitherto examined, a further set of results 
bearing on this point will be presented. The actual tests were done at the very 
beginning of this work, essentially to show how much the equilibrium param- 
eters varied by varying the concentration of serum. Such a control was needed 
since the homologous and heterologous antihemagglutinin titers of any serum 
are not the same, and thus the two sets of equilibrium measurements were al- 
ways performed at different concentrations of serum. We expected consider- 
able heterogeneity as antihaptenlc sera were shown by several workers (21-25) 
to have a  standard deviation in equilibrium constants  of about  16-fold, and 
we have looked into this problem on rabbit sera against three strains of influ- 
enza virus and obtained values between 6- and 10-fold (19). 
The method of testing was the conventional way of demonstrating hetero- 
geneity: the equilibrium Constant against  the homologous antigen was deter- 
mined at several concentrations of the serum. A  trend in the observed values 
(lowering of K  with increasing dilution of serum) is the mark of heterogeneity. 
The measurements  in Table V show that  a  typical cross-stimulated serum 340  ORIGINAL ANTIGENIC  SIN.  I 
scores as  completely homogeneous:  there  is  no  more  than  -4-  4%  variation, 
whether  the  equilibrium  constants  or  the  number  of antibody molecules at 
each level of the 16-fold range are considered. We have done similar tests on 
a  set of sera, with two measurements at serum concentrations 20- to 100-fold 
apart; the results were the same. This finding, entirely unexpected, is in line 
with the evidence of Table IV and sets such sera apart from all immune re- 
sponses, primary or secondary. 
To complete the picture, it should be added that this behavior holds strictly 
only for the  14-day bleeds after vaccination.  In some of the sera taken from 
the  same  group  of  children  42  days  after  vaccination  there  were  signs  of 
TABLE V 
Dependence of Equilibrium Parameters on Cor~entralion 
Dilution of serum 
1/lOO 
11300 
11500 
11750 
1/1200 
1/1600 
Serum A/7; La ~eer, 1954 (9) 
11.10 
11.04 
11.08 
11.01 
11.01 
11.05 
A 
15.50 
15.58 
15.54 
15.46 
15.58 
15.51 
aliA 
4.82 
4.79 
4.83 
4.82 
4.82 
4.88 
The equilibrium constants (K), concentrations of antibody moleeules/ml (A),  and anti- 
hemaggiutinin titers/ml (aliA) are given in log10 units. 
inhomogeneity: apart from the bulk of antibody molecules behaving like those 
shown in Table V, there was also a  small fraction with properties of anti-SW 
antibodies.  In the other  test group which  had received the SW-vaccine in a 
water-in-oil adjuvant and where samples of serum were collected only in the 
6th wk after vaccination, all sera we examined contained a  minority of anti- 
bodies  which  reacted  only  with  the  vaccinating  antigen,  but  not  with  the 
"original"  antigen,  FM1  virus.  For reasons  which  will  be developed in  the 
Discussion,  and on  experimental evidence to  be presented in the  companion 
paper, we believe this to be a  superimposed primary response and not a  nec- 
essary consequence of stimulation with a  cross-reacting antigen. 
DISCUSSION 
As far as interpretation goes, we have to make a new start since any simple 
instructive or selective hypothesis was untenable before we set out on the ex- 
periments. They have become even less tenable as both postulate, for different 
reasons, antibody populations that are heterogeneous, and neither can account 
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made at the immunological level and specify events in immunologic terms, a 
hypothesis accounting for them would remain precarious  if it  did not also 
tally with what we know about the production of proteins. 
The cell, as we see it today, is a repository of information only part of which 
is expressed at any one time. The induction of protein synthesis starts in the 
nucleus when the repressive control is lifted from a  segment of DNA.  This 
segment is then copied into a messenger RNA which, in its turn, is translated 
into the gene product by the appropriate  cytoplasmic machinery. In  micro- 
organisms at least, the derepressed segment may allow production of several 
proteins, usually involved at consecutive stages of a  particular cellular func- 
tion. If removal of a  repressor is mediated through an extrinsic inducer mole- 
cule, it is common to find among the series of induced proteins also a permease. 
Permeases are specific for the inducer and capable of trapping and concentrat- 
ing it inside the cell. Thus, while primary induction requires a relatively high 
concentration of inducer, once a permease has been produced that cell will be 
more prone to make the same series of proteins subsequently since it can be 
derepressed at lower external concentrations of the inducer. 
Translating all this into immunologic terms,  we have  a  large number of 
cells that come into contact with the primary antigen. Some may take it up, 
some may not, but when the antigen gets into the cells there is a second hurdle 
to overcome: it must combine with and remove a repressor from the DNA. If 
both operations are successful, the cell will start producing antibody, and we 
postulate that it will also produce some sort of trapping mechanism, which in 
this case may be  the antibody molecule itself. The population of antibody 
molecules produced primarily will be heterogeneous as there are many ways 
in which a gamma globulin can be more or less complementary to an antigenic 
determinant, and all of these possibilities have a chance of being realized. When 
the same antigen is given as  secondary booster,  considerably smaller doses 
will suffice to produce anamnestic response since the antigen will be trapped 
by those cells  (rand their offspring) which have been successfully induced by 
the primary exposure. And even among these the most avid trappers will get 
the lion's share of antigen, with the consequence that the secondary response 
should be due to the most avid sector of the antibody-producing population. 
Both these consequences of the hypothesis are well established experimental 
facts, as is a  third, namely that a  smaller booster dose gives a  more  specific 
response than a larger one. 
How would all this work when a  cross-reacting heterologous antigen is in- 
troduced secondarily? The first consequence we can foresee is that since it is 
cross-reacting it will be cross-trapped. Thus, given a smallish dose, it will not 
reach those cells where it would normally induce a primary response, but end 
up in some others which had some past experience of the antigen given first. 
Once in these cells, there is the second hurdle to overcome, and here we can 342  ORIGINAL ANTIGENIC SIN.  I 
distinguish three possibilities. If every cell that has trapped the second antigen 
can also be derepressed by it, the response should be essentially the same as 
it would be to homologous boosting. We have no instance of this in our ma- 
terial, but this is precisely what Dubert has found some years ago  (26),  and 
what has since  been puzzling many immunologists. He  used closely related 
modified albumins as primary and secondary antigens; his rabbits  produced 
antibody to the first antigen only, the extreme case of the Original Antigenic 
Sin.  Then we can envisage another situation where only a  small fraction of 
the cells that successfully trap the second antigen will also be derepressed by 
it. (This is a more likely alternative since trapping is a simple binary reaction, 
while derepression  is  ternary,  the  inducer  competing  with  the  operator  for 
the repressor).  Such a  state of affairs would make for a  more homogeneous 
response since it originates in a narrow sector only of the primary population. 
This would fit the case of the FM1-SW pair. And there is also a  third possi- 
bility, when the antigen is trapped,  but incapable of inducing antibody pro- 
duction in the cell  that has  trapped it.  In  this form the  Original Antigenic 
Sin would be manifested by rendering the vaccine less effective than it would 
be in a virgin population of cells, i.e., in a nonvaccinated host. We have a  case 
approaching  this  situation in  the pair  FM1-PR8  (13,  27),  and  this  area  is 
obviously open to direct testing by using a wide range of related antigens and 
appropriate methods of evaluation. 
The presence of a  specific  trapping  mechanism distinguishes the sensitized 
from  the  nonsensitized organism,  and  on  it  rests  the  qualitative  difference 
(28)  between the primary and secondary response. Simple instructive models 
do not allow for such differences, and their inductive-instructive modification 
by Monod (29) and Pappenheimer (30) would account for quantitative differ- 
ences only. So would all selective models, whether they envisage selection and 
proliferation at the cellular or subcellular level. The development and nature 
of the  trapping mechanism itself is  left deliberately unspecified: the  experi- 
mental material, restricted to anamnestic responses, can do no more  than re- 
veal or rule out its presence. Indeed, a  sequence involving two kinds of cells 
for the primary response is entirely compatible with the model, and the differ- 
entia]  radiosensitivity of  the  primary response  as  well  as  Fishman's  recent 
results (31, 32)  would render this alternative the rather more likely. Whether 
the trapping occurs through a permease unrelated to antibody (29, 30),  through 
sessile  antibody (33),  through excreted and  homing antibody (34)  or through 
the  ingenious mechanism proposed  by Eisen  and  Karush  (35),  remains to 
be decided by future work. 
SUMMARY 
When primary immunity is boosted not by the homologous but by a  cross- 
reacting vaccine, the newly formed antibodies react better with the primary S, FAZEKAS  DE ST.GROTH AND  R. G. WEBSTER  343 
antigen than with the antigen actually eliciting the response. This phenomenon 
bears the name of Original Antigenic  Sin  (1). 
It is  shown that  the number  of antibody molecules produced against  the 
original and the vaccinating antigen is the same; that each of these molecules 
is capable of reacting  with both antigens;  that  the activity of an  antiserum 
can be completely absorbed with  either  antigen;  that  both  residual  and  ad- 
sorbed-dissociated  fractions  of  antibody  exhibit  the  same  relative  affinities 
towards the two antigens as did the native serum; that, unlike standard  pri- 
mary  and  secondary  responses,  the  population  of antibody  molecules  char- 
acterizing the Original Antigenic Sin is homogeneous; that each molecule has 
a  lower equilibrium constant  (i.e.  higher avidity) against the original antigen 
than against the antigen stimulating the present response; and that all equilib- 
rium constants  are typical of secondary antibody. 
It is concluded that  the Original  Antigenic  Sin is a  partial  anamnestic  re- 
sponse, a related antigen stimulating  that sector only of the originally primed 
cells which  is destined  to produce cross-reacting  antibody. 
A hypothesis is developed according  to which the basic difference between 
primary  and  secondary reactivity  rests on the presence of a  trapping  mech- 
anism  that  allows anamnestic  production  of antibody against lower doses of 
the  homologous  antigen.  Such a  mechanism  is  capable of cross-trapping  re- 
lated  antigens,  thus  preventing  a  standard  primary  response  and  allowing 
manifestations of Original Antigenic Sin. 
It is a pleasure to thank Dr. T. Francis, Jr., Dr. F. M. Davenport, and Dr. A. V. Hennessy 
for their stimulating interest and for making available material from field trials with influenza 
vaccines. 
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